Equity Profile

IDXX

IDEXX LABS INC

Health CareHealth Care Equipment$44.3B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and maintain competitiveness.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDXX Q2-2026 Earnings Preview

Context

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry industries. Operating in the Health Care sector, the company plays a crucial role in animal health, leveraging technology to improve diagnostics and treatment outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.46%

Avg Stock Reaction

+6.39%

Last Quarter Recap

In Q1-2026, IDEXX reported an EPS of $3.47, slightly beating estimates by 1.49%. The stock had a modest reaction, declining by 0.03% the next day.

Management Promises & Guidance

Focus on expanding diagnostic product offerings.
Commitment to enhancing customer service and support.
Plans to invest in technology to improve operational efficiency.

Expectations

Wall Street Expectations

Overall expectations are mixed as investors look for signs of continued growth in a competitive market. The upcoming earnings report will be crucial in determining whether IDEXX can maintain its growth trajectory.

Bull Case

If IDEXX reports strong earnings and revenue growth, it could signal robust demand for its diagnostic products, leading to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a decline in stock price as investors reassess the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact investor sentiment.

How have diagnostic product sales performed this quarter?

Sales performance in this area is vital for understanding the company's growth and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for strong sales growth in diagnostic products, given recent trends in the veterinary market.

Supporting Evidence

The company's historical performance shows a 75% EPS beat rate, indicating stronger-than-expected results are possible.

Options pricing suggests a larger move than historical averages, indicating heightened investor interest.

Recent trends in animal health spending may support stronger sales than analysts anticipate.

Key Risk

If diagnostic product sales exceed expectations, it could invalidate the cautious outlook currently held by analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized to assess IDEXX's resilience in a competitive market.

Bull Confirmed If

An EPS of $3.60 or higher would confirm strong profitability and growth.

Bear Confirmed If

An EPS below $3.30 would raise concerns about the company's ability to maintain its growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±17.90%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±17.9% while IDXX has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.3%

Calls (3K)P/C Ratio: 2.14Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEXX beats expectations, history suggests a potential stock increase of around 8.77%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of about 0.73%, prompting reevaluation of growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic product launches.
2Insights into customer demand trends in the veterinary market.
3Management's commentary on operational efficiencies and cost management.
4Updates on any strategic partnerships or collaborations.
5Guidance on future revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and maintain competitiveness.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDXX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.46%

Avg Stock Reaction

+6.39%

Last Quarter Recap

In Q1-2026, IDEXX reported an EPS of $3.47, slightly beating estimates by 1.49%. The stock had a modest reaction, declining by 0.03% the next day.

Management Promises & Guidance

Focus on expanding diagnostic product offerings.
Commitment to enhancing customer service and support.
Plans to invest in technology to improve operational efficiency.

Expectations

Wall Street Expectations

Bull Case

If IDEXX reports strong earnings and revenue growth, it could signal robust demand for its diagnostic products, leading to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a decline in stock price as investors reassess the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

EPS is a critical measure of profitability, and a significant deviation from expectations could impact investor sentiment.

How have diagnostic product sales performed this quarter?

Sales performance in this area is vital for understanding the company's growth and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for strong sales growth in diagnostic products, given recent trends in the veterinary market.

Supporting Evidence

The company's historical performance shows a 75% EPS beat rate, indicating stronger-than-expected results are possible.

Options pricing suggests a larger move than historical averages, indicating heightened investor interest.

Recent trends in animal health spending may support stronger sales than analysts anticipate.

Key Risk

If diagnostic product sales exceed expectations, it could invalidate the cautious outlook currently held by analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely scrutinized to assess IDEXX's resilience in a competitive market.

Bull Confirmed If

An EPS of $3.60 or higher would confirm strong profitability and growth.

Bear Confirmed If

An EPS below $3.30 would raise concerns about the company's ability to maintain its growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±17.90%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±17.9% while IDXX has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.3%

Calls (3K)P/C Ratio: 2.14Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEXX beats expectations, history suggests a potential stock increase of around 8.77%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of about 0.73%, prompting reevaluation of growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic product launches.
2Insights into customer demand trends in the veterinary market.
3Management's commentary on operational efficiencies and cost management.
4Updates on any strategic partnerships or collaborations.
5Guidance on future revenue growth expectations.